Abstract:Background There is increasing interest in the role of brain-derived neurotrophic factor (BDNF) in the onset and course of schizophrenia, but there are conflicting reports about serum levels of BDNF in patients with schizophrenia. Aim Conduct a meta-analysis combining studies from China and other countries that have evaluated the relationship of serum BDNF levels to schizophrenia. Method We used Cochrane methodology and RevMan 5.1 software to identify and pool the results of studies. Electronic searches of western and Chinese registries and follow-up assessment of references located 268 potential articles. Twenty-five articles (20 in English and 5 in Chinese) published before December 2011 that used case-control methods, included patients with schizophrenia who had no concurrent disorders, and used ELISA technology to assess serum BDNF were included in the analysis. The main outcome was the pooled standardized mean difference (SMD) between cases and controls. The quality of the studies was independently assessed by two raters using the GRADE system. The heterogeneity, sensitivity and potential publication bias of the studies was evaluated using RevMan. Results The pooled sample included 1663 patients with schizophrenia and 1355 controls. Fifteen of the included studies were rated as ‘poor quality’ and 10 were rated as ‘very poor quality’. The results of the studies were quite heterogenous (I2=95%) but subgroup analyses found that the heterogeneity was not related to country of origin, sample size, age, gender, prior use of antipsychotic medication, or study quality. The pooled SMD (computed using a random-effect model because of study heterogeneity) was -0.74 (95% CI, -0.99∼-0.50; Z=5.99, p<0.001). Sensitivity analysis found that the result was stable and there was no evidence of publication bias. Conclusion Despite the robust statistical findings of lower serum BDNF in patients with schizophrenia than in controls, given the low quality of the available studies and the substantial heterogeneity between studies, the evidence of lower serum BDNF in patients with schizophrenia must be considered ‘weak’. The potential use of serum BDNF as a biomarker for schizophrenia must wait until higher-quality prospective studies that follow patients over time and that use uniform selection and monitoring procedures confirm these preliminary results.

Expression and Significance of Plasma BDNF in Patients with Schizophrenia

Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics.

Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia.

Low BDNF is Associated with Cognitive Impairment in Chronic Patients with Schizophrenia

Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia

Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Schizophrenia: A Systematic Review

Interaction of BDNF with Cytokines in Chronic Schizophrenia.

Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction

Plasma Level of Brain-Derived Neurotrophic Factor and the Related Analysis in Depressive Patients with Suicide Attempt

747 – Brain-derived Neurotrophic Factor and B-Cell Lymphoma Leukemia-2 Plasma Levels in Patients with Subsyndromal Symptomatic Depression

Peripheral Blood BDNF-TrkB Signaling in First-Episode, Drug-Free Patients with Major Depressive Disorder and Schizophrenia.

Depressive Symptoms in Schizophrenia Patients: A Possible Relationship Between SIRT1 and BDNF.

BDNF As a Biomarker in Diagnosis and Evaluation of Treatment for Schizophrenia and Depression.

Correlation study of brain-derived neurotrophic factor, EEG γ activity and cognitive function in first-episode schizophrenia

Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment.

Analysis of plasma brain-derived neurotrophic factor levels in patients with anxiety disorders

Decreased Plasma BDNF Levels of Patients with Somatization Disorder

Gender difference in association of cognition with BDNF in chronic schizophrenia.

Brain-derived neurotrophic factor gene mRNA and protein expression in patients with bipolar disorder

Brain Derived Neurotrophic Factor (BDNF) Gene in Peripheral Blood Cells of Stable Schizophrenia

An Analysis of Serum Levels of BDNF and Relative Factors in Depressive Patients